These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35145407)

  • 1. Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus.
    Suvorov A; Gupalova T; Desheva Y; Kramskaya T; Bormotova E; Koroleva I; Kopteva O; Leontieva G
    Front Pharmacol; 2021; 12():807256. PubMed ID: 35145407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease.
    Taghinezhad-S S; Mohseni AH; Bermúdez-Humarán LG; Casolaro V; Cortes-Perez NG; Keyvani H; Simal-Gandara J
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34066443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
    Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
    Front Immunol; 2021; 12():744887. PubMed ID: 34712232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    Front Immunol; 2021; 12():719077. PubMed ID: 34394127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models.
    Zhou R; Wang P; Wong YC; Xu H; Lau SY; Liu L; Mok BW; Peng Q; Liu N; Woo KF; Deng S; Tam RC; Huang H; Zhang AJ; Zhou D; Zhou B; Chan CY; Du Z; Yang D; Au KK; Yuen KY; Chen H; Chen Z
    EBioMedicine; 2022 Jan; 75():103762. PubMed ID: 34942445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity.
    Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D
    bioRxiv; 2021 Jun; ():. PubMed ID: 34075383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
    Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
    Front Immunol; 2021; 12():772240. PubMed ID: 34858430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
    Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
    Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D
    Front Immunol; 2021; 12():748103. PubMed ID: 34867974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2.
    Cho H; Jang Y; Park KH; Choi H; Nowakowska A; Lee HJ; Kim M; Kang MH; Kim JH; Shin HY; Oh YK; Kim YB
    NPJ Vaccines; 2021 Mar; 6(1):37. PubMed ID: 33741992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosting Vaccine-Elicited Respiratory Mucosal and Systemic COVID-19 Immunity in Mice With the Oral
    Xu J; Ren Z; Cao K; Li X; Yang J; Luo X; Zhu L; Wang X; Ding L; Liang J; Jin D; Yuan T; Li L; Xu J
    Front Nutr; 2021; 8():789242. PubMed ID: 35004816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and
    Jawalagatti V; Kirthika P; Park JY; Hewawaduge C; Lee JH
    J Adv Res; 2022 Feb; 36():211-222. PubMed ID: 35116175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified porous silicon microparticle promotes mucosal delivery of SARS-CoV-2 antigen and induction of potent and durable systemic and mucosal T helper 1 skewed protective immunity.
    Adam A; Shi Q; Wang B; Zou J; Mai J; Osman SR; Wu W; Xie X; Aguilar PV; Bao X; Shi PY; Shen H; Wang T
    bioRxiv; 2021 Nov; ():. PubMed ID: 34845456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a Live Probiotic Vaccine Based on the
    Desheva Y; Leontieva G; Kramskaya T; Gupalova T; Losev I; Kuleshevich E; Bormotova E; Kopteva O; Kudar P; Suvorov A
    Microorganisms; 2021 Nov; 9(12):. PubMed ID: 34946050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19.
    Varadhachary A; Chatterjee D; Garza J; Garr RP; Foley C; Letkeman A; Dean J; Haug D; Breeze J; Traylor R; Malek A; Nath R; Linbeck L
    medRxiv; 2020 Aug; ():. PubMed ID: 32817976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of SARS-CoV-2-Specific IgA in the Human Milk of COVID-19 Vaccinated Lactating Health Care Workers.
    Valcarce V; Stafford LS; Neu J; Cacho N; Parker L; Mueller M; Burchfield DJ; Li N; Larkin J
    Breastfeed Med; 2021 Dec; 16(12):1004-1009. PubMed ID: 34427487
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.